Ovarian malignancy risk-994

Test info

  
Ovarian malignancy risk
  
994
  
LAB994
  
MSO
  
ROMA OVA-1 OVA1
  

The ROMA® (Risk of Ovarian Malignancy Algorithm) calculation combines the results of the Roche Elecsys HE4 assay, Elecsys CA 125 II assay and menopausal status into a numerical score (Roche). The ROMA value is intended to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery. ROMA Calculation is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned and not yet referred to an oncologist. ROMA values must be interpreted in conjunction with an independent clinical and radiological assessment. The test is not intended as a screening or stand-alone diagnostic assay.

Specimen

  

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of Biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R).

It is recommended to ask all patients who may be indicated for this test about Biotin supplementation. Patients should be cautioned to stop Biotin consumption at least 72 hours prior to the collection of a sample.

  
Serum
  
  
1.75 mL
  
1.0 mL
Submission of the minimum volume does not allow for repeat testing
  

Immediatley following collection, mix sample by gently inverting 5 times

  
  1. Allow sample to clot for a minimum of 30 minutes
  2. Spin within two (2) hours of sample collection
  

Gold serum separator (SST) tube

  
  
  1. Allow sample to clot
  2. Spin
  3. Transfer serum to a Transfer vial/tube with cap - 12mL (LabCorp) labelled as "serum" within two (2) hours of sample collection
  
  

Molecular Medicare Billing Request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

  

Refrigerated (preferred) - 14 days

Ambient - 5 days

  
  • Gross hemolysis

Performance

  
LabCorp Burlington (140045): R-NX
  
Mo - Fr
  
4 days
  

Electrochemiluminescence Immunoassay (ECLIA)

Clinical and Interpretive info

  

Cancer Antigen (CA) 125:

0.0 - 38.1 01 U/mL

HE4:

0.0 - 61.2 01 pmol/L

ROMA score:

Premenopausal women:

≥1.14: high likelihood of finding malignancy
<1.14: low likelihood of finding malignancy

Postmenopausal women:

≥2.99: high likelihood of finding malignancy
<2.99: low likelihood of finding malignancy

  
Biotin supplement interference - see patient preparation

Billing

  
This test may require preauthorization from the insurance provider. Check the payer guidelines and, if needed, obtain the pre-authorization prior to sample collection.
  
81500
  
Yes
  
Result 10334-1
  

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Molecular Medicare Billing Request

Tracking

  
05/22/2019
  
05/23/2024
  
03/31/2022